Showing 5751-5760 of 5956 results for "".
- New CorneaGen Interactive Education Program To Offer Free Online Training for Surgeonshttps://modernod.com/news/new-corneagen-interactive-education-program-to-offer-free-online-training-for-all-surgeons/2479755/CorneaGen is adding interactive, online courses to its free education program for surgeons around the world. Utilizing an online platform designed for universities, CorneaGen will offer instruction in cutting-edge procedures such as Nano-Thin DSEK and best practices for using transplant devices.
- Cell Care Therapeutics Raises $4.3 Million in Seed Fundinghttps://modernod.com/news/cell-care-therapeutics-raises-4-3-million-in-seed-funding/2479765/Cell Care Therapeutics announced the closing of a $4.3 million seed round investment from a syndicate of individual investors. This round of funding will be used to develop Cell Care’s manufacturing platform and to ad
- IDx and Topcon Sign Exclusive AI Platform Agreement For the U.S. Markethttps://modernod.com/news/idx-and-topcon-sign-exclusive-ai-platform-agreement-for-the-u-s-market/2479766/AI diagnostics company IDx and Topcon have signed an exclusivity agreement that will allow the companies to scale delivery of AI-based diagnostic solutions in the United States. Terms of the deal were not disclosed. The agreement grants exclusive rights to IDx in the US as the only
- OWL to Host Signature Event and Awards Ceremony at AAO 2018https://modernod.com/news/owl-to-host-signature-event-and-awards-ceremony-at-aao-2018/2479767/OWL: Advancing Diversity in Leadership (OWL) announced that it will host its annual OWL Signature Event and Awards Ceremony at the American Academy of Ophthalmology (AAO). OWL’s largest event of the year will take place on Sunday, October 28, 2018 from 5:30-7:00 p.m., at Revel Motor Row in Chicag
- Orasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directorshttps://modernod.com/news/orasis-announces-the-appointment-of-jeffry-weinhuff-as-chairman-of-the-board-of-directors/2479771/Orasis Pharmaceuticals announced the appointment of Jeffry Weinhuff as chairman of the board of directors. As a managing partner of Visionary Ventures, Mr. Weinhuff joins the Orasis board of directors in conjunction with the recent Series B financing led by Visionary Ventures, a venture capital f
- Takeda Gets Japanese Approval for $62 Billion Shire Purchasehttps://modernod.com/news/takeda-gets-japanese-approval-for-62-billion-shire-purchase/2479773/Takeda Pharmaceutical reported that Japan’s Fair Trade Commission had approved its $62 billion acquisition of Shire, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker, according to
- I-MED Pharma Partners With Quidel to Introduce I-Lid ’N Lash, I-Relief, and SMTube to the US Markethttps://modernod.com/news/i-med-pharma-partners-with-quidel-to-introduce-i-lid-n-lash-i-relief-and-smtube-to-the-us-market/2479777/I-MED Pharma, a company specializing in dry eye diagnosis and management, announced the signing of an exclusive distribution agreement with Quidel Corporation, a leading provider of rapid diagnostic testing solutions, cellular-based virology assays, and molecular diagnostic systems, for I-MED Pha
- Oculus Announces New Joystick for the Keratograph 5M With Release Functionhttps://modernod.com/news/oculus-announces-new-joystick-for-the-keratograph-5m-with-release-function/2479779/As of September 2018, the Oculus Keratograph 5M comes equipped with a new joystick including a release function. This enables the user to capture images and video sequences with the simple push of a button on the devi
- Aura Biosciences to Present Phase 1b/2 Clinical Data for AU-011 at AAOhttps://modernod.com/news/aura-biosciences-to-present-phase-1b-2-clinical-data-for-au-011-at-aao/2479786/Aura Biosciences announced that it will be highlighting its phase 1b/2 clinical data for AU-011, the company’s lead product candidate for the primary treatment of choroidal melanoma, in two oral presentations at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting being held October 27
- EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious Uveitishttps://modernod.com/news/eyepoint-pharmaceuticals-receives-fda-approval-of-yutiq-for-noninfectious-uveitis/2479787/EyePoint Pharmaceuticals announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Yutiq utilizes the company’s Durasert drug delivery technology and is a non-bioerodible i